Virology Research Today is a free monthly online journal that collates and summarizes the latest research about Virology, including details on viruses, pathology, classification, definitions.

Volume 3 (2007), Issue 7 (July)

1. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
   J Med Virol, 79(8): 1047-54. [Abstract] [Full-text]
2. Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors.
   J Gastroenterol Hepatol, 22(7): 1078-1085. [Abstract] [Full-text]
3. Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: A pathological and virological study.
   Leuk Lymphoma, 48(7): 1323-31. [Abstract] [Full-text]
4. Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level.
   Hepatol Res, 37(9): 692-700. [Abstract] [Full-text]
5. Identification of a Novel Immunosubversion Mechanism Mediated by a Virologue of the B-Lymphocyte Receptor TACI.
   Clin Vaccine Immunol, 14(7): 907-17. [Abstract] [Full-text]
6. Virological features of hepatitis B virus-associated nephropathy in Japan.
   J Med Virol, 79(9): 1305-11. [Abstract] [Full-text]
7. Dose-by-dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection.
   J Med Virol, 79(9): 1401-5. [Abstract] [Full-text]
8. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
   J Med Virol, 79(9): 1254-60. [Abstract] [Full-text]
9. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.
   J Acquir Immune Defic Syndr, 45(4): 411-7. [Abstract] [Full-text]
10. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Gut, 56(8): 1111-6. [Abstract] [Full-text]
11. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    AIDS, 21(12): 1579-89. [Abstract] [Full-text]
12. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
    AIDS, 21(12): 1555-9. [Abstract] [Full-text]
13. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.
    AIDS, 21(12): 1547-54. [Abstract] [Full-text]
14. Analysis of relation between virologic responses and immunologic responses, patient's factors in AIDS clinical trials using a semiparametric mixed-effects model.
    Biom J, 49(3): 406-15. [Abstract] [Full-text]
15. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy.
    HIV Med, 8(6): 406-10. [Abstract] [Full-text]

© 2005-2008 Virology Research Today. All Rights Reserved.